Please upgrade your browser.
The conference is far from typical. There’s no foundation underwriting it, no public relations firm managing it, and no hotel ballroom. Instead there is a scholarship system, donated food, and an educational center that still features the old-time river town set that once welcomed casino-goers.
Researchers at the Institute of Bioengineering and Nanotechnology (IBN) have successfully generated human kidney cells from human embryonic stem cells in vitro.
Researchers have identified mutation-defined subtypes of clear cell renal cell carcinoma (ccRCC) that have distinct clinical outcomes.
Chemists at the University of California, Riverside have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer.
Does Timing of Cytoreductive Nephrectomy Impact Patient Survival With Metastatic Renal Cell Carcinoma?
OBJECTIVE: To compare outcomes of metastatic renal cell carcinoma (mRCC) patients who underwent primary cytoreductive nephrectomy (CRN), followed by adjuvant sunitinib therapy, vs those who underwent primary sunitinib therapy before planned CRN.
Fatal adverse events occurred more than twice as often in cancer patients treated with mTOR inhibitors compared with control therapies, a review of multiple clinical trials showed.
Students and families who journey through the emotional weekend experience many highs and lows. For the Deckman’s of Mountain Top. It’s a year to celebrate. They said THON has been a huge help for their family as their son Caleb battled kidney cancer.
The National Minority Quality Forum announced today a collaboration between its National Health Index (NHI) and Microsoft Corporation to launch the National Clinical Trial Network (NCTN) designed to a
The National Minority Quality Forum announced today a collaboration between its National Health Index (NHI) and Microsoft Corporation to launch the National Clinical Trial Network (NCTN) designed to address important challenges in clinical trials—accelerating recruitment and diversity. The relationship allows NCTN to deliver a platform that provides a comprehensive database of clinical trial options to providers.
KCA and CCF partner on cancer research projects for a sixth year.
The association of autosomal dominant polycystic kidney disease with renal cell carcinoma is infrequent. A case of bilateral renal cell carcinoma in conjunction with autosomal dominant polycystic kidney disease is presented. The discussion emphasizes pertinent diagnostic and therapeutic considerations.
|NeonCRM by Neon One|